L-Carnitine (Injectable)

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: approved drug label available for levocarnitine injection

Storage

Store vials at controlled room temperature 25 C; avoid excessive heat; protect from freezing; discard unused portion because no preservative is present.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Hypothyroidism (may interfere with thyroid hormone action): L-Carnitine acts as a functional thyroid hormone antagonist at the receptor level; it inhibits thyroid hormone entry into cell nuclei, reducing gene transactivation by T3 and T4; subjects with hypothyroidism should be aware that L-Carnitine supplementation may worsen hypothyroid symptoms or reduce the effectiveness of levothyroxine therapy.
• Concurrent levothyroxine or thyroid hormone therapy: L-Carnitine's peripheral anti-thyroid action may reduce the effectiveness of thyroid replacement therapy; monitor thyroid function if co-administering.
• End-stage renal disease (ESRD) without dialysis: L-Carnitine is renally excreted; accumulation to toxic levels is possible in severe renal failure; patients on hemodialysis may actually require carnitine supplementation due to dialytic losses, but administration should be clinically supervised.
• Seizure disorder: rare reports of increased seizure frequency in subjects with pre-existing seizure disorders using L-Carnitine supplementation; mechanism not fully characterized; use with caution.
• Known hypersensitivity to L-Carnitine or injectable formulation excipients.
• Concurrent anticoagulant therapy (warfarin): case reports suggest L-Carnitine potentiates the anticoagulant effect of warfarin; INR monitoring is warranted if co-administering.
• Trimethylaminuria (fish odor syndrome): subjects with impaired FMO3 enzyme activity cannot efficiently oxidize TMA to TMAO; even injectable carnitine metabolism may produce systemic TMA accumulation and severe body odor.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Fishy body odor (trimethylaminuria-like effect): the most characteristically reported adverse effect at higher injectable doses; occurs as L-Carnitine metabolism produces trimethylamine as a byproduct; some individuals are poor metabolizers of TMA to TMAO; the odor can be significant and socially notable; injectable routes reduce but do not eliminate this risk compared to oral.
• Injection site pain and local reactions: injectable L-Carnitine solutions are often hyperosmolar; subcutaneous administration can cause burning, stinging, and localized irritation; IM injection is sometimes preferred for volume and tolerability reasons.
• Nausea and gastrointestinal discomfort: more common with oral forms but reported with high-dose injectable use.
• Diarrhea: at high doses; related to systemic carnitine load.
• Headache: mild; occasional; mechanism not characterized.
• Restlessness or mild insomnia: reported in sensitive individuals at higher doses; carnitine's role in mitochondrial activation may have a mild stimulatory quality in some subjects.
• Hypothyroidism worsening: functional anti-thyroid effect in subjects with compromised thyroid function; thyroid-sensitive subjects should monitor thyroid panel.
• Elevated TMAO (trimethylamine N-oxide): cardiovascular risk concern at chronic high doses; the injectable route mitigates but does not entirely eliminate TMAO production; relevance at standard research protocol doses is uncertain.
• Muscle weakness in subjects with carnitine-related metabolic disorders: paradoxical; subjects with organic acidemias or other disorders of carnitine metabolism may experience unusual responses to supplementation.

Compatibility

The relationships below come from the source site's internal engine and were Carnitor label states compatibility/stability in 0.9% sodium chloride or lactated Ringer's at specified concentrations for up to 24 hours at room temperature. independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

None listed.

Reported contraindicated combinations:

None listed.

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cf801cc4-775e-433d-9d32-e5d9a98981d3
• PubMed search: L-Carnitine (Injectable)
• DailyMed label search: levocarnitine injection